The California Walnut Commission announced today the third annual Power of 3 global marketing campaign to increase awareness about the benefits of omega-3s an
The California Walnut Commission announced today the third annual Power of 3 global marketing campaign to increase awareness about the benefits of omega-3s an
New Delhi [India], March 3 (ANI/NewsVoir): The California Walnut Commission announced today the third annual Power of 3 global marketing campaign to increase awareness about the benefits of omega-3s and highlight how walnuts are an excellent source of plant-based omega-3 ALA (alpha-linolenic acid).
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST
Allschwil, Switzerland - June 2
, 2021
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study SOS-AMI to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia s P2Y
12 receptor antagonist, in suspected acute myocardial infarction (AMI).
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, each year more than 80